SARS-CoV-2 SNV Genotyping Test Technology

doi:10.13523/j.cb.2204054

China Biotechnology

2022, Vol. 42

Issue (8): 63-73 DOI: 10.13523/j.cb.2204054

SARS-CoV-2 SNV Genotyping Test Technology

WANG Tao-xue^1,^2,³,LIU Qian^1,^2,³,QI Hao^1,^2,^3,^*(

)

1. School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, China
2. Key Laboratory of Systems Bioengineering of Ministry of Education, Tianjin University, Tianjin 300072, China
3. Collaborative Innovation Center of Chemical Science and Engineering, Syn Bio Research Platform, Tianjin University, Tianjin 300072, China

Download:

HTML

PDF(2039KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

The global pandemic of the COVID-19 has had a major impact on the entire human society, and human beings are facing challenges such as fiscal stimulus, financial stress, and debt restructuring. Before the emergence of specific therapeutic drugs and methods, large-scale population screening and isolation has become the most effective method for epidemic management. However, the new strain of coronavirus this time has shown a very high genetic variability, with a statistical mutation rate of more than 2.3‰ as of March 31st, 2022. So far, new highly infectious virus strains have been emerging, and the number of mutant strains officially warned by the World Health Organization has reached 7. Therefore, in the next virus prevention and control and research, we not only need to detect SARS-CoV-2, but also need to explore accurate and practical single nucleotide variation (SNV) genotyping techniques, especially for large-scale population screening. It is not only necessary to obtain information on the SRAS-CoV-2, but also to accurately and quickly distinguish variant strains with higher infectivity and virulence. This paper briefly introduces the infection and mutation mechanism of the virus, and focuses on the classification and review of the existing main SARS-CoV-2 SNV genotyping techniques, hoping to provide insight into the development of new detection technologies.

Key words： COVID-19 SARS-CoV-2 test Single nucleotide varication (SNV)

Received: 21 April 2022 Published: 07 September 2022

ZTFLH:

Q934.9

Corresponding Authors: Hao QI E-mail: haoq@tju.edu.cn

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Tao-xue WANG
	Qian LIU
	Hao QI

Cite this article:

WANG Tao-xue,LIU Qian,QI Hao. SARS-CoV-2 SNV Genotyping Test Technology. China Biotechnology, 2022, 42(8): 63-73.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.2204054 OR https://manu60.magtech.com.cn/biotech/Y2022/V42/I8/63

Fig.1 Schematic diagram of SARS-CoV-2 genome

Table 1 Existing SARS-CoV-2 variants

Fig.2 Schematic diagram of SARS-CoV-2 SNV physicochemical detection technology (a) HRM diagram to identify single nucleotide variation (b) HRM diagram to identify D614G mutation site (c) SERS diagram to identify single nucleotide variation

Table 2 Summary of SARS-CoV-2 genotyping detection platforms

Table 3 Comparison of RT-qPCR detection targets

Table 4 CRISPR/Cas detection platforms for SARS-CoV-2


[1]	Li B S, Deng A P, Li K B, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. Nature Communications, 2022, 13: 460. doi: 10.1038/s41467-022-28089-y

[2]	Boni M F, Lemey P, Jiang X W, et al. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nature Microbiology, 2020, 5(11): 1408-1417. doi: 10.1038/s41564-020-0771-4

[3]	Hou W. Characterization of codon usage pattern in SARS-CoV-2. Virology Journal, 2020, 17(1): 138. doi: 10.1186/s12985-020-01395-x

[4]	Wu C R, Liu Y, Yang Y Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharmaceutica Sinica B, 2020, 10(5): 766-788. doi: 10.1016/j.apsb.2020.02.008

[5]	Sanjuán R, Domingo-Calap P. Mechanisms of viral mutation. Cellular and Molecular Life Sciences, 2016, 73(23): 4433-4448. pmid: 27392606

[6]	Sevajol M, Subissi L, Decroly E, et al. Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus. Virus Research, 2014, 194: 90-99. doi: 10.1016/j.virusres.2014.10.008 pmid: 25451065

[7]	Smith E C, Denison M R. Coronaviruses as DNA wannabes: a new model for the regulation of RNA virus replication fidelity. PLoS Pathogens, 2013, 9(12): e1003760. doi: 10.1371/journal.ppat.1003760

[8]	Song H D, Tu C C, Zhang G W, et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102(7): 2430-2435.

[9]	Su Y C F, Bahl J, Joseph U, et al. Phylodynamics of H1N1/2009 influenza reveals the transition from host adaptation to immune-driven selection. Nature Communications, 2015, 6: 7952. doi: 10.1038/ncomms8952

[10]	Kirchdoerfer R N, Ward A B. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nature Communications, 2019, 10: 2342. doi: 10.1038/s41467-019-10280-3 pmid: 31138817

[11]	Korber B, Fischer W M, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell, 2020, 182(4): 812-827.e19. doi: S0092-8674(20)30820-5 pmid: 32697968

[12]	Meng B, Kemp S A, Papa G, et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Reports, 2021, 35(13): 109292. doi: 10.1016/j.celrep.2021.109292

[13]	Calistri P, Amato L, Puglia I, et al. Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs. International Journal of Infectious Diseases: Official Publication of the International Society for Infectious Diseases, 2021, 105: 753-755.

[14]	Davies N G, Abbott S, Barnard R C, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science, 2021, 372(6538): eabg3055. doi: 10.1126/science.abg3055

[15]	Collier D A, de Marco A, Ferreira I A T M, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature, 2021, 593(7857): 136-141. doi: 10.1038/s41586-021-03412-7

[16]	Moustafa A M, Bianco C, Denu L, et al. Comparative analysis of emerging B.1.1.7+E484K SARS-CoV-2 isolates. Open Forum Infectious Diseases, 2021, 8(7): ofab300. doi: 10.1093/ofid/ofab300

[17]	Garcia-Beltran W F, Lam E C, St Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell, 2021, 184(9): 2372-2383.e9. doi: 10.1016/j.cell.2021.03.013 pmid: 33743213

[18]	Faria N R, Mellan T A, Whittaker C, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science, 2021, 372(6544): 815-821. doi: 10.1126/science.abh2644 pmid: 33853970

[19]	Radvak P, Kwon H J, Kosikova M, et al. SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains. Nature Communications, 2021, 12(1): 6559. doi: 10.1038/s41467-021-26803-w pmid: 34772941

[20]	Greaney A J, Loes A N, Crawford K H D, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host & Microbe, 2021, 29(3): 463-476.e6.

[21]	Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. Global Challenges, 2017, 1(1): 33-46. doi: 10.1002/gch2.1018

[22]	McMahan K, Giffin V, Tostanoski L H, et al. Reduced pathogenicity of the SARS-CoV-2 Omicron variant in hamsters. Med, 2022, 3(4): 262-268.e4. doi: 10.1016/j.medj.2022.03.004

[23]	Chan M C. HKUMed finds Omicron SARS-CoV-2 can infect faster and better than Delta in human Bronchus but with less severe infection in lung. Brazilian Journal of Implantology and Health Sciences, 2022, 4(1): 50-54. doi: 10.36557/2674-8169.2022v4n1p50-54

[24]	Gazali F M, Nuhamunada M, Nabilla R, et al. Detection of SARS-CoV-2 spike protein D614G mutation by qPCR-HRM analysis. Heliyon, 2021, 7(9): e07936. doi: 10.1016/j.heliyon.2021.e07936

[25]	Aoki A, Mori Y, Okamoto Y, et al. Development of a genotyping platform for SARS-CoV-2 variants using high-resolution melting analysis. Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy, 2021, 27(9): 1336-1341. doi: 10.1016/j.jiac.2021.06.007

[26]	Diaz-Garcia H, Guzmán-Ortiz A L, Angeles-Floriano T, et al. Genotyping of the major SARS-CoV-2 clade by short-amplicon high-resolution melting (SA-HRM) analysis. Genes, 2021, 12(4): 531. doi: 10.3390/genes12040531

[27]	Zhao Y N, Lee A N, Composto K, et al. A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations. Emerging Microbes & Infections, 2021, 10(1): 994-997.

[28]	Sitjar J, Liao J D, Lee H, et al. Challenges of SERS technology as a non-nucleic acid or-antigen detection method for SARS-CoV-2 virus and its variants. Biosensors & Bioelectronics, 2021, 181: 113153. doi: 10.1016/j.bios.2021.113153

[29]	Zavyalova E, Ambartsumyan O, Zhdanov G, et al. SERS-based aptasensor for rapid quantitative detection of SARS-CoV-2. Nanomaterials (Basel, Switzerland), 2021, 11(6): 1394.

[30]	Awada C, Abdullah M M B, Traboulsi H, et al. SARS-CoV-2 receptor binding domain as a stable-potential target for SARS-CoV-2 detection by surface-enhanced Raman spectroscopy. Sensors (Basel, Switzerland), 2021, 21(13): 4617. doi: 10.3390/s21134617

[31]	Kowalczyk A, Krajczewski J, Kowalik A, et al. New strategy for the gene mutation identification using surface enhanced Raman spectroscopy (SERS). Biosensors and Bioelectronics, 2019, 132: 326-332. doi: S0956-5663(19)30222-2 pmid: 30897539

[32]	Hernandez M M, Banu R, Gonzalez-Reiche A S, et al. Robust clinical detection of SARS-CoV-2 variants by RT-PCR/MALDI-TOF multitarget approach. Journal of Medical Virology, 2022, 94(4): 1606-1616. doi: 10.1002/jmv.27510

[33]	Stelzl E, Kessler H H, Mustafa H G, et al. Alternative detection of SARS-CoV-2 RNA by a new assay based on mass spectrometry. Clinical Chemistry and Laboratory Medicine, 2021, 59(12): 1998-2002. doi: 10.1515/cclm-2021-0483

[34]	World Health Organization/Europe. Methods for the detection and characterisation of SARS-CoV-2 variants: first update.[2021-12-20]. WHO/EURO:2021-2148-41903-62832.

[35]	Suzuki O, Dong O M, Howard R M, et al. Characterizing the pharmacogenome using molecular inversion probes for targeted next-generation sequencing. Pharmacogenomics, 2019, 20(14): 1005-1020. doi: 10.2217/pgs-2019-0057 pmid: 31559919

[36]	Lu R J, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London, England), 2020, 395(10224): 565-574. doi: 10.1016/S0140-6736(20)30251-8

[37]	Borkakoty B, Bali N K. TSP-based PCR for rapid identification of L and S type strains of SARS-CoV-2. Indian Journal of Medical Microbiology, 2021, 39(1): 73-80. doi: 10.1016/j.ijmmb.2021.01.003

[38]	Sandoval Torrientes M, Castelló Abietar C, Boga Riveiro J, et al. A novel single nucleotide polymorphism assay for the detection of N501Y SARS-CoV-2 variants. Journal of Virological Methods, 2021, 294: 114143. doi: 10.1016/j.jviromet.2021.114143

[39]	Perchetti G A, Zhu H Y, Mills M G, et al. Specific allelic discrimination of N501Y and other SARS-CoV-2 mutations by ddPCR detects B.1.1.7 lineage in Washington State. Journal of Medical Virology, 2021, 93(10): 5931-5941. doi: 10.1002/jmv.27155 pmid: 34170525

[40]	Iijima T, Ando S, Kanamori D, et al. Detection of SARS-CoV-2 and the L452R spike mutation using reverse transcription loop-mediated isothermal amplification plus bioluminescent assay in real-time (RT-LAMP-BART). PLoS One, 2022, 17(3): e0265748. doi: 10.1371/journal.pone.0265748

[41]	Liang Y H, Lin H Q, Zou L R, et al. CRISPR-Cas12a-based detection for the major SARS-CoV-2 variants of concern. Microbiology Spectrum, 2021, 9(3): e0101721. doi: 10.1128/Spectrum.01017-21

[42]	Stanley K K, Szewczuk E. Multiplexed tandem PCR: gene profiling from small amounts of RNA using SYBR Green detection. Nucleic Acids Research, 2005, 33(20): e180. doi: 10.1093/nar/gni182 pmid: 16314310

[43]	Corman V M, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus(2019-nCoV) by real-time RT-PCR. Eurosurveillance, 2020, 25(3):23-30.

[44]	Nörz D, Grunwald M, Olearo F, et al. Evaluation of a fully automated high-throughput SARS-CoV-2 multiplex qPCR assay with built-in screening functionality for del-HV69/70- and N501Y variants such as B.1.1.7. Journal of Clinical Virology, 2021, 141: 104894. doi: 10.1016/j.jcv.2021.104894

[45]	Neopane P, Nypaver J, Shrestha R, et al. SARS-CoV-2 variants detection using TaqMan SARS-CoV-2 mutation panel molecular genotyping assays. Infection and Drug Resistance, 2021, 14: 4471-4479. doi: 10.2147/IDR.S335583 pmid: 34737587

[46]	Suo T, Liu X J, Feng J P, et al. ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens. Emerging Microbes & Infections, 2020, 9(1): 1259-1268.

[47]	Craw P, Balachandran W. Isothermal nucleic acid amplification technologies for point-of-care diagnostics: a critical review. Lab on a Chip, 2012, 12(14): 2469-2486. doi: 10.1039/c2lc40100b

[48]	Li Y, Li S Y, Wang J, et al. CRISPR/cas systems towards next-generation biosensing. Trends in Biotechnology, 2019, 37(7): 730-743. doi: 10.1016/j.tibtech.2018.12.005

[49]	Kellner M J, Koob J G, Gootenberg J S, et al. SHERLOCK: nucleic acid detection with CRISPR nucleases. Nature Protocols, 2019, 14(10): 2986-3012. doi: 10.1038/s41596-019-0210-2 pmid: 31548639

[50]	Ding X, Yin K, Li Z, et al. All-in-one dual CRISPR-Cas12a (AIOD-CRISPR) assay: a case for rapid, ultrasensitive and visual detection of novel coronavirus SARS-CoV-2 and HIV virus. BioRxiv: the Preprint Server for Biology, 2020.DOI: 10.1101/2020.03.19.998724. doi: 10.1101/2020.03.19.998724

[51]	Azhar M, Phutela R, Kumar M, et al. Rapid and accurate nucleobase detection using FnCas9 and its application in COVID-19 diagnosis. Biosensors and Bioelectronics, 2021, 183: 113207. doi: 10.1016/j.bios.2021.113207

[52]	Guo L, Sun X H, Wang X G, et al. SARS-CoV-2 detection with CRISPR diagnostics. Cell Discovery, 2020, 6: 34. doi: 10.1038/s41421-020-0174-y pmid: 32435508

[53]	Broughton J P, Deng X D, Yu G X, et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nature Biotechnology, 2020, 38(7): 870-874. doi: 10.1038/s41587-020-0513-4 pmid: 32300245

[54]	Ponce-Rojas J C, Costello M S, Proctor D A, et al. A fast and accessible method for the isolation of RNA, DNA, and protein to facilitate the detection of SARS-CoV-2. Journal of Clinical Microbiology, 2021, 59(4): e02403-e02420.

[55]	Wang Y X, Xue T, Wang M J, et al. CRISPR-Cas13a cascade-based viral RNA assay for detecting SARS-CoV-2 and its mutations in clinical samples. Sensors and Actuators B, Chemical, 2022, 362: 131765. doi: 10.1016/j.snb.2022.131765

[56]	Wang Y X, Zhang Y, Chen J B, et al. Detection of SARS-CoV-2 and its mutated variants via CRISPR-Cas13-based transcription amplification. Analytical Chemistry, 2021, 93(7): 3393-3402. doi: 10.1021/acs.analchem.0c04303

[57]	Hale R, Crowley P, Dervisevic S, et al. Development of a multiplex tandem PCR (MT-PCR) assay for the detection of emerging SARS-CoV-2 variants. Viruses, 2021, 13(10): 2028. doi: 10.3390/v13102028

[1]	YANG Yi,ZHANG Qing-yun,MEI Kun-rong. Progress and Current Situation of SARS-CoV-2 Subunit Vaccine Development[J]. China Biotechnology, 2022, 42(5): 124-138.

[2]	WU Dong,XIAO Feng,YUAN Min,CHEN Yu-bao,ZHANG Hong-xiang. Transformation of Scientific and Technological Achievements in Biomedical Field in China from 2011 to 2020[J]. China Biotechnology, 2022, 42(1/2): 191-201.

[3]	YUN Tao,GONG Yue,GU Peng,XU Bing-bing,LI Jin,ZHAO Xi-chen. Present Situation and Prospect of International S&T Cooperation between China and Countries Participating in the “Belt and Road” Initiative to Combat COVID-19[J]. China Biotechnology, 2021, 41(7): 110-121.

[4]	XU Ye-chun,LIU Hong,LI Jian-feng,SHEN Jing-shan,JIANG Hua-liang. Recent Progress in Drug Development against COVID-19[J]. China Biotechnology, 2021, 41(6): 111-118.

[5]	FU Gui-e,LI Jin,GENG Pei-ran,SHEN Meng-qiu,ZHANG Jin-qian-nan,ZHAO Xi-chen. A Study on COVID-19 Prevention Force of Typical Cities in the Guangdong-Hong Kong-Macao Greater Bay Area Based on the Medical Perspective[J]. China Biotechnology, 2021, 41(12): 125-140.

[6]	WU Rui-jun,LI Zhi-fei,ZHANG Xin,PU Run,AO Yi,SUN Yan-rong. Development and Prospect of Antibody Drugs for SARS-CoV-2[J]. China Biotechnology, 2020, 40(5): 1-6.

[7]	XIE Hua-ling,LV Lu-cheng,YANG Yan-ping. Patent Analysis of Global Coronavirus Vaccine[J]. China Biotechnology, 2020, 40(1-2): 57-64.

[8]	ZHU Xiao-li,HUANG Cui,MA Li-li,ZHANG Chao,GONG Yue,ZHAO Wan-yu,ZHAO Xiu-fang,GUO Wen-jiao,PENG Hao,ZHANG Ji,LIANG Hui-gang. Research Advances of Novel Coronavirus Disease (COVID-19)[J]. China Biotechnology, 2020, 40(1-2): 38-50.

[9]	LIN Fu-yu,LIU Jin-yi,CHENG Yong-qing. Progress of Interferon α1b Research and Clinical Use Against SARS-CoV-2[J]. China Biotechnology, 2020, 40(12): 1-7.

[10]	LIAO Xiao-yan,CHEN Li-li. The Progress in the Development of COVID-19 Vaccine[J]. China Biotechnology, 2020, 40(12): 8-17.

[11]	CHEN Li-jun,QU Jing-jing,XIANG Charlie. Therapeutic Potentials, Clinical Studies, and Application Prospects of Mesenchymal Stem Cells in 2019 Novel Coronavirus (COVID-19)[J]. China Biotechnology, 2020, 40(11): 43-55.

Viewed

Full text

Abstract

Cited

Shared

Discussed